Stock Track | Omnicell Delivers Strong Q3 2024 Results, Raises Full-Year Guidance

Stock Track

Oct 30, 2024

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions, reported impressive financial results for the third quarter of 2024, surpassing analyst expectations for both earnings and revenue.

The company posted adjusted earnings per share of $0.56 for the quarter, beating the consensus estimate of $0.40. Revenue came in at $282.4 million, exceeding the estimated $280.4 million, driven by robust demand for Omnicell's innovative solutions and services.

Reflecting its strong performance, Omnicell raised its full-year 2024 guidance. The company now expects non-GAAP EBITDA to range between $129 million and $134 million, and non-GAAP earnings per share to be in the range of $1.65 to $1.72.

Despite a challenging macroeconomic environment for some healthcare customers, Omnicell's outcomes-centric approach and customer-first focus have resonated well with the market. The appointment of Nnamdi Njoku as Executive Vice President and Chief Operating Officer is expected to further support the company's operational scaling and growth initiatives.

Randall Lipps, Omnicell's Chairman, President, and CEO, expressed confidence in the company's trajectory, stating, "As the macroeconomic environment within the healthcare sector continues to show signs of stabilization, we believe our outcomes-centric innovation and customer-first focus is resonating with the market."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1109206427"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109206427\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1109206427?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 18:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109206427","market":"hk","top_or_hot":-1,"title":"Stock Track | Omnicell Delivers Strong Q3 2024 Results, Raises Full-Year Guidance","media":"Stock Track","content":"<p>Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions, reported impressive financial results for the third quarter of 2024, surpassing analyst expectations for both earnings and revenue.</p>\n\n<p>The company posted adjusted earnings per share of $0.56 for the quarter, beating the consensus estimate of $0.40. Revenue came in at $282.4 million, exceeding the estimated $280.4 million, driven by robust demand for Omnicell's innovative solutions and services.</p>\n\n<p>Reflecting its strong performance, Omnicell raised its full-year 2024 guidance. The company now expects non-GAAP EBITDA to range between $129 million and $134 million, and non-GAAP earnings per share to be in the range of $1.65 to $1.72.</p>\n\n<p>Despite a challenging macroeconomic environment for some healthcare customers, Omnicell's outcomes-centric approach and customer-first focus have resonated well with the market. The appointment of Nnamdi Njoku as Executive Vice President and Chief Operating Officer is expected to further support the company's operational scaling and growth initiatives.</p>\n\n<p>Randall Lipps, Omnicell's Chairman, President, and CEO, expressed confidence in the company's trajectory, stating, \"As the macroeconomic environment within the healthcare sector continues to show signs of stabilization, we believe our outcomes-centric innovation and customer-first focus is resonating with the market.\"</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Omnicell Delivers Strong Q3 2024 Results, Raises Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Omnicell Delivers Strong Q3 2024 Results, Raises Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-30 18:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions, reported impressive financial results for the third quarter of 2024, surpassing analyst expectations for both earnings and revenue.</p>\n\n<p>The company posted adjusted earnings per share of $0.56 for the quarter, beating the consensus estimate of $0.40. Revenue came in at $282.4 million, exceeding the estimated $280.4 million, driven by robust demand for Omnicell's innovative solutions and services.</p>\n\n<p>Reflecting its strong performance, Omnicell raised its full-year 2024 guidance. The company now expects non-GAAP EBITDA to range between $129 million and $134 million, and non-GAAP earnings per share to be in the range of $1.65 to $1.72.</p>\n\n<p>Despite a challenging macroeconomic environment for some healthcare customers, Omnicell's outcomes-centric approach and customer-first focus have resonated well with the market. The appointment of Nnamdi Njoku as Executive Vice President and Chief Operating Officer is expected to further support the company's operational scaling and growth initiatives.</p>\n\n<p>Randall Lipps, Omnicell's Chairman, President, and CEO, expressed confidence in the company's trajectory, stating, \"As the macroeconomic environment within the healthcare sector continues to show signs of stabilization, we believe our outcomes-centric innovation and customer-first focus is resonating with the market.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMCL","symbol_name":"Omnicell","start_time":0,"source_url":"","article_id":"1109206427","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109206427","pubTimestamp":1730285798,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Omnicell, Inc. , a leading provider of medication management solutions, reported impressive financial results for the third quarter of 2024, surpassing analyst expectations for both earnings and revenue.The company posted adjusted earnings per share of $0.56 for the quarter, beating the consensus estimate of $0.40. Revenue came in at $282.4 million, exceeding the estimated $280.4 million, driven by robust demand for Omnicell's innovative solutions and services.Reflecting its strong performance, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMCL":"Omnicell"},"translate_title":"股票赛道Omnicell 2024年第三季度业绩强劲，上调全年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":1},"content_text":"Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions, reported impressive financial results for the third quarter of 2024, surpassing analyst expectations for both earnings and revenue.\nThe company posted adjusted earnings per share of $0.56 for the quarter, beating the consensus estimate of $0.40. Revenue came in at $282.4 million, exceeding the estimated $280.4 million, driven by robust demand for Omnicell's innovative solutions and services.\nReflecting its strong performance, Omnicell raised its full-year 2024 guidance. The company now expects non-GAAP EBITDA to range between $129 million and $134 million, and non-GAAP earnings per share to be in the range of $1.65 to $1.72.\nDespite a challenging macroeconomic environment for some healthcare customers, Omnicell's outcomes-centric approach and customer-first focus have resonated well with the market. The appointment of Nnamdi Njoku as Executive Vice President and Chief Operating Officer is expected to further support the company's operational scaling and growth initiatives.\nRandall Lipps, Omnicell's Chairman, President, and CEO, expressed confidence in the company's trajectory, stating, \"As the macroeconomic environment within the healthcare sector continues to show signs of stabilization, we believe our outcomes-centric innovation and customer-first focus is resonating with the market.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}